Association between miR-124 rs531564 and miR-100 rs1834306 polymorphisms and cervical cancer: a meta-analysis

Aim: To explore the correlations between miR-124 rs531564 and miR-100 rs1834306 polymorphisms and cervical cancer (CC). Ma-terials and Methods: Relevant studies were searched from the electronic databases Embase, Cochrane library, and PubMed updated to January 2017, as well as through literature tracing. Studies were selected based on strict criteria, followed by the included studies which were conducted with quality assessment using Newcastle-Ottawa Scale (NOS). With odds ratios (ORs) and corresponding 95% confi-dence intervals (95% CIs) as effect indicators, meta-analysis for exploring the correlations between rs531564 and rs1834306 polymor-phisms and CC was performed using R 3.12 software. Using Egger’s test, publication bias was elevated for the included studies. In addition, sensitivity analysis was carried out. Results: There were a total of four eligible studies, involving 3,707 participators (including 1,592 CC patients and 2,115 healthy controls). The NOS scores of the included studies were 5-7, indicating a high quality. Meta-analysis showed that all genetic models of rs531564 were statistically significant (p < 0.05), indicating that rs531564 was associated with the occurrence of CC. Nevertheless, the situation for rs1834306 was exactly the opposite. Egger’s test for rs531564 showed no publication bias, suggesting that our results were reliable. Sensitivity analysis showed that the pooled results of rs531564 were stable in general. Conclusion: These indicated that rs531564 was correlated with the development of CC, but not rs1834306.

Cervical cancer; microRNAs; rs531564; rs1834306; Meta-analysis.

[1] Tarney C.M., Han J.: “Postcoital bleeding: a review on etiology, di-agnosis, and management”. Obstet Gynecol Int, 2014, 2014, 192087.

[2] Mcguire S.: “World Cancer Report 2014”. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015”. Adv. Nutr., 2016, 7, 418.

[3] Dunne E.F., Park I.U.: “HPV and HPV-associated diseases”. Infect. Dis. Clin. North Am., 2013, 27, 765.

[4] Tsikouras P., Zervoudis S., Manav B., Tomara E., Iatrakis G., Ro-manidis C., et al.: “Cervical cancer: screening, diagnosis and stag-ing”. J. BUON., 2016, 21, 320.

[5] Alhan E.: “Human papillomavirus (HPV) vaccines”. Cocuk. Enfek-siyon Dergisi., 2009, 03, 50-5.

[6] Tran N.P., Hung C.F., Roden R., Wu T.C.: “Control of HPV Infection and Related Cancer Through Vaccination: Springer Berlin Heidel-berg 2014.

[7] Scarinci I.C., Garcia F.A., Kobetz E., Partridge E.E., Brandt H.M,, et al.: “Cervical cancer prevention”. Cancer, 2010, 116, 2531.

[8] Holley C.L., Topkara V.K.: “An Introduction to Small Non-coding RNAs: miRNA and snoRNA”. Cardiovasc. Drugs Ther., 2011, 25, 151.

[9] Sun G., Yan J., Noltner K., Feng J., Li H., Sarkis D.A., et al.: “SNPs in human miRNA genes affect biogenesis and function”. RNA, 2009, 15, 1640.

[10] Sethupathy P., Collins F.S.: “MicroRNA target site polymorphisms and human disease”. Trends Genet., 2008, 24, 489.

[11] Furuta M., Kozaki K.S., Arii S., Imoto I., Inazawa J.: “miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma”. Carcinogenesis, 2010, 31, 766.

[12] Wilting S.M., Boerdonk R.A.V., Henken F.E., Meijer C.J., Diosdado B., Meijer G.A., et al.: “Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer”. Mol. Can-cer, 2010, 9, 167.

[13] Chim C.S., Wong K.Y., Leung C.Y., Chung L.P., Hui P.K., Chan S.Y., et al.: “Epigenetic inactivation of the hsa-miR-203 in haematological malignancies”. J Hematol Oncol, 2013, 6, 16.

[14] Xia J., Wu Z., Yu C., He W., Zheng H., He Y., et al.: “miR-124 in-hibits cell proliferation in gastric cancer through down􀀁regulation of SPHK1”. J. Pathol., 2012, 227, 470.

[15] Zhang X., Cai D., Meng L., Wang B.: “MicroRNA-124 inhibits pro-liferation, invasion, migration and epithelial-mesenchymal transition of cervical carcinoma cells by targeting astrocyte-elevated gene-1”. Oncol. Rep., 2016, 36, 2321.

[16] Li W.J., Wang Y., Gong Y., Tu C., Feng T.B., Qi C.J.: “MicroRNA-124 rs531564 Polymorphism and Cancer Risk: A Meta-analysis”. Asian Pac. J. Cancer Prev., 2015, 16, 7905.

[17] Li B.H., Zhou J.S., Ye F., Cheng X.D., Zhou C.Y., Lu W.G., et al.: “Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein”. Eur. J. Can-cer, 2011, 47, 2166.

[18] Kato R., Nishi H., Nagamitsu Y., Sasaki T., Isaka K.: “Abstract 4378: miR-100 mediates resistance to paclitaxel in cervical cancer cells”. Cancer Res., 2014, 74, 4378.

[19] Zhu J., Yang L., You W., Cui X., Chen Y., Hu J., et al.: “Genetic vari-ation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China”. Int. J. Clin. Exp. Pathol., 2015, 8, 7332.

[20] Boni V., Zarate R., Villa J.C., Bandrés E., Gomez M.A., Maiello E., et al.: “Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan”. Pharmacogenomics J., 2011, 11, 429.

[21] Wells G., Shea B., O¡¯connell D., Peterson J., Welch V., Losos M., et al.: “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011”. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, 2011.

[22] Ward R., Carroll R.J.: “Testing Hardy–Weinberg equilibrium with a simple root-mean-square statistic”. Biostatistics, 2013, 15, 74.

[23] Lau J., Ioannidis J.P., Schmid C.H.: “Quantitative synthesis in sys-tematic reviews”. Ann Intern Med, 1997, 127, 820.

[24] Higgins J., Thompson S.G., Deeks J.J., Altman D.G.: “Measuring inconsistency in meta-analyses”. BMJ, 2003, 327, 557.

[25] Feng R.N., Zhao C., Sun C.H., Li Y.: “Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus”. PLoS One, 2011, 6, e18480.

[26] Egger M., Smith G.D., Phillips A.N.: “Principles and procedures”. BMJ, 1997, 315, 1533.

[27] Li C., Wang X., Yan Z., Zhang Y., Liu S., Yang J., et al.: “The asso-ciation between polymorphisms in microRNA genes and cervical cancer in a Chinese Han population”. Oncotarget, 2017, 8, 87914.

[28] Wu H., Zhang J.: “miR-124 rs531564 polymorphism influences ge-netic susceptibility to cervical cancer”. Int. J. Clin. Exp. Med., 2014, 7, 5847-51.

[29] Xiong X., Cheng J., Liu X., Tang S., Luo X.: “[Correlation analysis between miR-124 rs531564 polymorphisms and susceptibility to cer-vical cancer]”. Nan Fang Yi Ke Da Xue Xue Bao, 2014, 34, 210.

[30] Xiong X.D., Luo X.P., Cheng J., Liu X., Li E.M., Zeng L.Q.: “A ge-netic variant in pre-miR-27a is associated with a reduced cervical cancer risk in southern Chinese women”. Gynecol. Oncol., 2014, 132, 450.

[31] Ye Y., Wang K.K., Gu J., Yang H., Lin J., Ajani J.A., et al.: “Genetic Variations in MicroRNA-Related Genes Are Novel Susceptibility Loci for Esophageal Cancer Risk”. Cancer Prev. Res., 2008, 1, 460.

[32] Wu C., Li M., Hu C., Duan H.: “Prognostic role of microRNA poly-morphisms in patients with advanced esophageal squamous cell car-cinoma receiving platinum-based chemotherapy”. Cancer Chemother. Pharmacol., 2014, 73, 335.